Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Learn more about the expert recommended optimal management of patients with NF1-associated tumors from this on-demand webcast with downloadable slides and an expert-authored commentary with answers to frequently asked questions.

Share

Program Content

Events

Activities

NF1 Current Understanding
NF1: Current State of Disease Understanding
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 21, 2024

Expires: November 20, 2025

NF1 Peripheral Nerve Sheath Tumors
NF1-Associated Peripheral Nerve Sheath Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 21, 2024

Expires: November 20, 2025

NF1 Gliomas
NF1-Associated Gliomas
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 21, 2024

Expires: November 20, 2025

Faculty

cover img faculity

Jaishri Blakeley, MD

The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Director, The Neurofibromatosis Therapeutic Acceleration Program
Director, the Johns Hopkins Comprehensive Neurofibromatosis Program
Professor of Neurology, Neurosurgery and Oncology
The Johns Hopkins School of Medicine
Baltimore, Maryland

cover img faculity

Miriam Bornhorst, MD

Neuro-Oncologist
Max Lacewell Endowed Brain Tumor Research Scholar
NF-Oncology
Ann & Robert H. Lurie Children’s Hospital
Stanley Manne Children’s Research Institute
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, Illinois

cover img faculity

Michael J. Fisher, MD

Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Center for Childhood Cancer Research and Division of Oncology
The Children’s Hospital of Philadelphia
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Alexion Pharmaceuticals and Springworks Therapeutics, Inc.

Alexion Pharmaceuticals

SpringWorks Therapeutics, Inc.